Tithi Biswas

List of Publications by Year in Descending Order

59 papers	546 citations	13 h-index	21 g-index
69 ext. papers	716 ext. citations	3.1 avg, IF	3.76 L-index

#	Paper	IF	Citations
59	Stereotactic body radiotherapy (SBRT) for T2N0 (>3 cm) non-small cell lung cancer: Outcomes and failure patterns. *Journal of Radiosurgery and SBRT*, **2021**, 7, 271-277	0.4	
58	An analysis of a large multi-institutional database reveals important associations between treatment parameters and clinical outcomes for stereotactic body radiotherapy (SBRT) of oligometastatic colorectal cancer.. *Radiotherapy and Oncology*, **2021**,	5.3	2
57	Pretreatment neutrophil-to-lymphocyte ratio as an important prognostic marker in stage III locally advanced non-small cell lung cancer: confirmatory results from the PROCLAIM phase III clinical trial. *Journal of Thoracic Disease*, **2021**, 13, 5617-5626	2.6	0
56	Volumetric burden of metastatic lesions drives outcomes in patients with extracranial oligometastatic disease. *Cancer Medicine*, **2021**, 10, 8091-8099	4.8	1
55	A Modeling Approach to Radiation Therapy in the Era of COVID-19. *JAMA Network Open*, **2021**, 4, e213850	10.4	
54	Analysis of patterns of care and benefit of thoracic radiotherapy for patients with stage IV NSCLC in the immunotherapy-era from a national hospital-based registry.. *Journal of Clinical Oncology*, **2021**, 39, 9123-9123	2.2	
53	Prognostic value of SUVmax on FDG-PET/CT before and after stereotactic body radiotherapy (SBRT) on recurrence and survival in early-stage non-small cell lung cancer (NSCLC).. *Journal of Clinical Oncology*, **2021**, 39, 8539-8539	2.2	
52	Role of radiation in extensive stage small cell lung cancer: a National Cancer Database registry analysis. *Future Oncology*, **2021**, 17, 2713-2724	3.6	1
51	Oligometastases: history of a hypothesis. *Annals of Palliative Medicine*, **2021**, 10, 5923-5930	1.7	10
50	Local Control After Stereotactic Body Radiation Therapy for Stage I Non-Small Cell Lung Cancer. *International Journal of Radiation Oncology Biology Physics*, **2021**, 110, 160-171	4	10
49	Modernizing Clinical Trial Eligibility Criteria: Recommendations of the ASCO-Friends of Cancer Research Prior Therapies Work Group. *Clinical Cancer Research*, **2021**, 27, 2408-2415	12.9	6
48	An international pooled analysis of SBRT outcomes to oligometastatic spine and non-spine bone metastases. *Radiotherapy and Oncology*, **2021**, 164, 98-103	5.3	1
47	Late metastatic presentation is associated with improved survival and delayed wide-spread progression after ablative stereotactic body radiotherapy for oligometastasis. *Cancer Medicine*, **2021**, 10, 6189-6198	4.8	3
46	Evaluation of Definitive Stereotactic Body Radiotherapy and Outcomes in Adults With Extracranial Oligometastasis. *JAMA Network Open*, **2020**, 3, e2026312	10.4	17
45	Using the Systemic Immune-Inflammation Index (SII) as a Mid-Treatment Marker for Survival among Patients with Stage-III Locally Advanced Non-Small Cell Lung Cancer (NSCLC). *International Journal of Environmental Research and Public Health*, **2020**, 17,	4.6	7
44	40: Patterns of Failure in Extra-Cranial Oligometastatic Patients Treated with Definitive Stereotactic Body Radiotherapy (SBRT). *Radiotherapy and Oncology*, **2020**, 150, S20-S21	5.3	
43	Automated Quality Assurance of OAR Contouring for Lung Cancer Based on Segmentation With Deep Active Learning. *Frontiers in Oncology*, **2020**, 10, 986	5.3	5

42	The changing landscape of stage III lung cancer: a literature review. *Expert Review of Anticancer Therapy*, **2020**, 20, 675-686	3.5	1
41	Tumor localization accuracy for high-precision radiotherapy during active breath-hold. *Radiotherapy and Oncology*, **2019**, 137, 145-152	5.3	3
40	Evaluating radiotherapy treatment delay using Failure Mode and Effects Analysis (FMEA). *Radiotherapy and Oncology*, **2019**, 137, 102-109	5.3	7
39	Diffuse Atypical Cystic Brain Metastases in ALK+ NSCLC Treated With Whole Brain Radiation and Second-Generation ALK-Targeted Therapy. *Practical Radiation Oncology*, **2019**, 9, e129-e133	2.8	1
38	A simple matrix to predict treatment success and long-term survival among patients undergoing pancreatectomy. *Hpb*, **2019**, 21, 204-211	3.8	2
37	An Integrated Framework Based on Full Monte Carlo Simulations for Double-Scattering Proton Therapy. *International Journal of Particle Therapy*, **2019**, 6, 31-41	1.5	
36	Pathologic Complete Response (pCR) and Survival of Women with Inflammatory Breast Cancer (IBC): An Analysis Based on Biologic Subtypes and Demographic Characteristics. *International Journal of Environmental Research and Public Health*, **2019**, 16,	4.6	14
35	The Association between Age, Comorbidities and Use of Radiotherapy in Women with Breast Cancer: Implications for Survival. *Medicines (Basel, Switzerland)*, **2018**, 5,	4.1	6
34	Post-operative radiation therapy (PORT) in resected non-small cell lung cancer (NSCLC): An updated population based analysis.. *Journal of Clinical Oncology*, **2018**, 36, 8522-8522	2.2	1
33	Demography and survival of inflammatory breast cancer (IBC) based on histological subtypes: A hospital-based registry analysis.. *Journal of Clinical Oncology*, **2018**, 36, e12587-e12587	2.2	
32	A multinational report of technical factors on stereotactic body radiotherapy for oligometastases. *Future Oncology*, **2017**, 13, 1081-1089	3.6	8
31	Perioperative chemotherapy versus postoperative chemoradiotherapy in patients with resectable gastric/gastroesophageal junction adenocarcinomas: A survival analysis of 5058 patients. *Cancer*, **2017**, 123, 2909-2917	6.4	20
30	Evaluation of interfractional variation of organs and displacement of catheters during high-dose-rate interstitial brachytherapy for gynecologic malignancies. *Brachytherapy*, **2017**, 16, 1192-1198	2.4	5
29	Local therapy for triple-negative breast cancer: a comprehensive review. *Future Oncology*, **2017**, 13, 1721-1730	3.6	8
28	Prognostic potential of neutrophil-to-lymphocyte ratio and lymphocyte nadir in stage III non-small-cell lung cancer. *Future Oncology*, **2017**, 13, 1405-1414	3.6	15
27	Multi-Institutional Experience of Stereotactic Ablative Radiation Therapy for Stage I Small Cell Lung Cancer. *International Journal of Radiation Oncology Biology Physics*, **2017**, 97, 362-371	4	57
26	Tumor control probability modeling for stereotactic body radiation therapy of early-stage lung cancer using multiple bio-physical models. *Radiotherapy and Oncology*, **2017**, 122, 286-294	5.3	35
25	The survival benefit of neoadjuvant chemotherapy and pCR among patients with advanced stage triple negative breast cancer. *Oncotarget*, **2017**, 8, 112712-112719	3.3	29

24	Radiosensitization of non-small-cell lung cancer cells and xenografts by the interactive effects of pemetrexed and methoxyamine. *Radiotherapy and Oncology*, **2016**, 121, 335-341	5.3	9
23	Inflammatory TNBC Breast Cancer: Demography and Clinical Outcome in a Large Cohort of Patients With TNBC. *Clinical Breast Cancer*, **2016**, 16, 212-6	3	15
22	Current topics in the multimodality treatment of locally advanced rectal cancer. *Future Oncology*, **2016**, 12, 963-79	3.6	1
21	Failure patterns and survival outcomes in triple negative breast cancer (TNBC): a 15 year comparison of 448 non-Hispanic black and white women. *SpringerPlus*, **2016**, 5, 756		8
20	Comparison of cisplatin/etoposide versus carboplatin/etoposide concurrent chemoradiation therapy for limited-stage small cell lung cancer (LS-SCLC) in the elderly population (age >65 years) using national SEER-Medicare data. *Practical Radiation Oncology*, **2016**, 6, e163-e169	2.8	7
19	Optimum treatment for mediastinal lymph node positive (N2) resectable non-small cell lung cancer: what is the role for surgery?. *Expert Review of Anticancer Therapy*, **2016**, 16, 1131-1144	3.5	
18	Primary squamous cell carcinoma of the prostate: a case report of a rare clinical entity. *Future Science OA*, **2015**, 1, FSO18	2.7	6
17	Complications from Stereotactic Body Radiotherapy for Lung Cancer. *Cancers*, **2015**, 7, 981-1004	6.6	60
16	Effect of Race and Insurance on the Outcome of Stage I Non-small Cell Lung Cancer. *Anticancer Research*, **2015**, 35, 4243-9	2.3	9
15	Important prognostic factors for lung cancer in tobacco predominant Eastern North Carolina: study based on a single cancer registry. *Lung Cancer*, **2014**, 84, 116-20	5.9	4
14	Chest wall and rib irradiation and toxicities of early-stage lung cancer patients treated with CyberKnife stereotactic body radiotherapy. *Future Oncology*, **2014**, 10, 2311-7	3.6	2
13	Controversies in the management of stage III non-small-cell lung cancer. *Expert Review of Anticancer Therapy*, **2014**, 14, 333-47	3.5	11
12	Race, insurance type, and stage of presentation among lung cancer patients. *SpringerPlus*, **2014**, 3, 710		10
11	Emerging applications of stereotactic body radiotherapy. *Future Oncology*, **2014**, 10, 1299-310	3.6	13
10	Comparison of cisplatin- versus carboplatin-based concurrent chemoradiation for limited-stage small cell lung cancer using SEER-Medicare data.. *Journal of Clinical Oncology*, **2014**, 32, 7596-7596	2.2	0
9	Intensity-modulated radiation therapy and volumetric-modulated arc therapy for adult craniospinal irradiation--a comparison with traditional techniques. *Medical Dosimetry*, **2013**, 38, 48-54	1.3	25
8	Primary pancreatic lymphoma: a population-based analysis using the SEER program. *American Journal of Clinical Oncology: Cancer Clinical Trials*, **2013**, 36, 38-43	2.7	23
7	The relation of race and type of health insurance to long-term risk of mortality among lung cancer patients in rural Eastern North Carolina. *North Carolina Medical Journal*, **2013**, 74, 464-9	0.6	5

6	Involved field radiation therapy following high dose chemotherapy and autologous stem cell transplant benefits local control and survival in refractory or recurrent Hodgkin lymphoma. *Radiotherapy and Oncology*, **2012**, 103, 367-72	5.3	26
5	Angiosarcoma of the breast: a rare clinicopathological entity. *American Journal of Clinical Oncology: Cancer Clinical Trials*, **2009**, 32, 582-6	2.7	28
4	Patterns and Timing of Initial Relapse in Patients with Hodgkin and Non-Hodgkin Lymphoma.. *Blood*, **2006**, 108, 3673-3673	2.2	2
3	Involved Field Radiation Therapy Following Autologous Stem Cell Rescue for Hodgkin and Non-Hodgkin Lymphoma - Is It Efficacious?.. *Blood*, **2006**, 108, 3676-3676	2.2	
2	Low-dose radiosurgery for benign intracranial lesions. *American Journal of Clinical Oncology: Cancer Clinical Trials*, **2003**, 26, 325-31	2.7	7
1	Coordinated control of a 3DOF cartesian robot and a shape memory alloy-actuated flexible needle for surgical interventions: a non-model-based control method. *Robotica*,1-18	2.1	